Annual review of pharmacology and toxicology最新文献_第2页

Targeting G Protein–Coupled Receptors in Immuno-Oncological Therapies 以免疫肿瘤疗法中的 G 蛋白偶联受体为靶点

IF 12.5 1区医学

Annual review of pharmacology and toxicology Pub Date : 2024-09-13 DOI: 10.1146/annurev-pharmtox-061724-080852

John Stagg, J. Silvio Gutkind

引用次数: 0

Advancements in Assays for Micro- and Nanoplastic Detection: Paving the Way for Biomonitoring and Exposomics Studies 微塑料和纳米塑料检测试验的进展：为生物监测和暴露组学研究铺平道路

IF 12.5 1区医学

Annual review of pharmacology and toxicology Pub Date : 2024-09-13 DOI: 10.1146/annurev-pharmtox-030424-112828

Kuanliang Shao, Runyu Zou, Zhuoyue Zhang, Laurens D.B. Mandemaker, Sarah Timbie, Ronald D. Smith, Amanda M. Durkin, Hanna M. Dusza, Florian Meirer, Bert M. Weckhuysen, Tanya L. Alderete, Roel Vermuelen, Douglas I. Walker

{"title":"Advancements in Assays for Micro- and Nanoplastic Detection: Paving the Way for Biomonitoring and Exposomics Studies","authors":"Kuanliang Shao, Runyu Zou, Zhuoyue Zhang, Laurens D.B. Mandemaker, Sarah Timbie, Ronald D. Smith, Amanda M. Durkin, Hanna M. Dusza, Florian Meirer, Bert M. Weckhuysen, Tanya L. Alderete, Roel Vermuelen, Douglas I. Walker","doi":"10.1146/annurev-pharmtox-030424-112828","DOIUrl":"https://doi.org/10.1146/annurev-pharmtox-030424-112828","url":null,"abstract":"Although plastic pollution and exposure to plastic-related compounds have received worldwide attention, health risks associated with micro- and nanoplastics (MNPs) are largely unknown. Emerging evidence suggests MNPs are present in human biofluids and tissue, including blood, breast milk, stool, lung tissue, and placenta; however, exposure assessment is limited and the extent of human exposure to MNPs is not well known. While there is a critical need to establish robust and scalable biomonitoring strategies to assess human exposure to MNPs and plastic-related chemicals, over 10,000 chemicals have been linked to plastic manufacturing with no existing standardized approaches to account for even a fraction of these exposures. This review provides an overview of the status of methods for measuring MNPs and associated plastic-related chemicals in humans, with a focus on approaches that could be adapted for population-wide biomonitoring and integration with biological response measures to develop hypotheses on potential health effects of plastic exposures. We also examine the exposure risks associated with the widespread use of chemical additives in plastics. Despite advancements in analytical techniques, there remains a pressing need for standardized measurement protocols and untargeted, high-throughput analysis methods to enable comprehensive MNP biomonitoring to identify key MNP exposures in human populations. This review aims to merge insights into the toxicological effects of MNPs and plastic additives with an evaluation of analytical challenges, advocating for enhanced research methods to fully assess, understand, and mitigate the public health implications of MNPs.","PeriodicalId":8057,"journal":{"name":"Annual review of pharmacology and toxicology","volume":"6 1","pages":""},"PeriodicalIF":12.5,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142265233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immunoregulation of Liver Fibrosis: New Opportunities for Antifibrotic Therapy 肝纤维化的免疫调节：抗纤维化疗法的新机遇

IF 12.5 1区医学

Annual review of pharmacology and toxicology Pub Date : 2024-09-11 DOI: 10.1146/annurev-pharmtox-020524-012013

Helene Gilgenkrantz, Rola Al Sayegh, Sophie Lotersztajn

引用次数: 0

Gut Microbiota–Related Biomarkers in Immuno-Oncology 免疫肿瘤学中与肠道微生物群相关的生物标记物

IF 12.5 1区医学

Annual review of pharmacology and toxicology Pub Date : 2024-09-11 DOI: 10.1146/annurev-pharmtox-061124-102218

Carolina Alves Costa Silva, Marine Fidelle, Andrew A. Almonte, Lisa Derosa, Laurence Zitvogel

{"title":"Gut Microbiota–Related Biomarkers in Immuno-Oncology","authors":"Carolina Alves Costa Silva, Marine Fidelle, Andrew A. Almonte, Lisa Derosa, Laurence Zitvogel","doi":"10.1146/annurev-pharmtox-061124-102218","DOIUrl":"https://doi.org/10.1146/annurev-pharmtox-061124-102218","url":null,"abstract":"Carcinogenesis is associated with the emergence of protracted intestinal dysbiosis and metabolic changes. Increasing evidence shows that gut microbiota–related biomarkers and microbiota-centered interventions are promising strategies to overcome resistance to immunotherapy. However, current standard methods for evaluating gut microbiota composition are cost- and time-consuming. The development of routine diagnostic tools for intestinal barrier alterations and dysbiosis constitutes a critical unmet medical need that can guide routine treatment and microbiota-centered intervention decisions in patients with cancer. In this review, we explore the influence of gut microbiota on cancer immunotherapy and highlight gut-associated biomarkers that have the potential to be transformed into simple diagnostic tools, thus guiding standard treatment decisions in the field of immuno-oncology. Mechanistic insights toward leveraging the complex relationship between cancer immunosurveillance, gut microbiota, and metabolism open exciting opportunities for developing novel biomarkers in immuno-oncology.","PeriodicalId":8057,"journal":{"name":"Annual review of pharmacology and toxicology","volume":"31 1","pages":""},"PeriodicalIF":12.5,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142225517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treating Sickle Cell Disease: Gene Therapy Approaches 治疗镰状细胞病：基因治疗方法

IF 12.5 1区医学

Annual review of pharmacology and toxicology Pub Date : 2024-09-11 DOI: 10.1146/annurev-pharmtox-022124-022000

Marina Cavazzana, Alice Corsia, Megane Brusson, Annarita Miccio, Michaela Semeraro

{"title":"Treating Sickle Cell Disease: Gene Therapy Approaches","authors":"Marina Cavazzana, Alice Corsia, Megane Brusson, Annarita Miccio, Michaela Semeraro","doi":"10.1146/annurev-pharmtox-022124-022000","DOIUrl":"https://doi.org/10.1146/annurev-pharmtox-022124-022000","url":null,"abstract":"Sickle cell disease (SCD) is a hereditary blood disorder characterized by the presence of abnormal hemoglobin molecules and thus distortion (sickling) of the red blood cells. SCD causes chronic pain and organ damage and shortens life expectancy. Gene therapy emerges as a potentially curative approach for people with SCD who lack a matched sibling donor for hematopoietic stem cell transplantation. Here, we review recent progress in gene therapy for SCD and focus on innovative technologies that target the genetic roots of the disease. We also review the challenges associated with gene therapy, including oncogenic risks, and the need for refined delivery methods. Despite these hurdles, the rapidly evolving landscape of gene therapy for SCD raises hope for a paradigm shift in the treatment of this debilitating disease. As research progresses, a deeper understanding of the molecular mechanisms involved and continuous improvements in gene-editing technologies promise to bring gene therapy for SCD closer to mainstream clinical application, offering a transformative, curative option for patients with this genetic disorder.","PeriodicalId":8057,"journal":{"name":"Annual review of pharmacology and toxicology","volume":"90 1","pages":""},"PeriodicalIF":12.5,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142199106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Weight Loss Blockbuster Development: A Role for Unimolecular Polypharmacology 减肥大片的开发：单分子多药理学的作用

IF 12.5 1区医学

Annual review of pharmacology and toxicology Pub Date : 2024-09-11 DOI: 10.1146/annurev-pharmtox-061324-011832

Qingtong Zhou, Guanyi Li, Kaini Hang, Jie Li, Dehua Yang, Ming-Wei Wang

{"title":"Weight Loss Blockbuster Development: A Role for Unimolecular Polypharmacology","authors":"Qingtong Zhou, Guanyi Li, Kaini Hang, Jie Li, Dehua Yang, Ming-Wei Wang","doi":"10.1146/annurev-pharmtox-061324-011832","DOIUrl":"https://doi.org/10.1146/annurev-pharmtox-061324-011832","url":null,"abstract":"Obesity and type 2 diabetes mellitus (T2DM) impact more than 2.5 billion adults worldwide, necessitating innovative therapeutic approaches. Unimolecular polypharmacology, which involves designing single molecules to target multiple receptors or pathways simultaneously, has revolutionized treatment strategies. Blockbuster drugs such as tirzepatide and retatrutide have shown unprecedented success in managing obesity and T2DM, demonstrating superior efficacy compared to conventional single agonists. Tirzepatide, in particular, has garnered tremendous attention for its remarkable effectiveness in promoting weight loss and improving glycemic control, while offering additional cardiovascular and renal benefits. Despite their promises, such therapeutic agents also face challenges that include gastrointestinal side effects, patient compliance issues, and body weight rebound after cessation of the treatment. Nonetheless, the development of these therapies marks a significant leap forward, underscoring the transformative potential of unimolecular polypharmacology in addressing metabolic diseases and paving the way for future innovations in personalized medicine.","PeriodicalId":8057,"journal":{"name":"Annual review of pharmacology and toxicology","volume":"42 1","pages":""},"PeriodicalIF":12.5,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142225516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pollution of Soil by Pharmaceuticals: Implications for Metazoan and Environmental Health. 药物对土壤的污染：对元虫和环境健康的影响。

IF 11.2 1区医学

Annual review of pharmacology and toxicology Pub Date : 2024-09-03 DOI: 10.1146/annurev-pharmtox-030124-111214

Chubin Zhang, Leon P Barron, Stephen R Stürzenbaum

引用次数: 0

Opportunities for Microphysiological Systems in Toxicity Testing of New Drug Modalities. 微观生理学系统在新药毒性测试中的机遇。

IF 11.2 1区医学

Annual review of pharmacology and toxicology Pub Date : 2024-09-03 DOI: 10.1146/annurev-pharmtox-061724-080621

Tengku Ibrahim Maulana, Nienke R Wevers, Theodora Kristoforus, Morgan Chandler, Henriette L Lanz, Jos Joore, Paul Vulto, Remi Villenave, Stefan Kustermann, Peter Loskill, Kristin M Bircsak

{"title":"Opportunities for Microphysiological Systems in Toxicity Testing of New Drug Modalities.","authors":"Tengku Ibrahim Maulana, Nienke R Wevers, Theodora Kristoforus, Morgan Chandler, Henriette L Lanz, Jos Joore, Paul Vulto, Remi Villenave, Stefan Kustermann, Peter Loskill, Kristin M Bircsak","doi":"10.1146/annurev-pharmtox-061724-080621","DOIUrl":"https://doi.org/10.1146/annurev-pharmtox-061724-080621","url":null,"abstract":"New drug modalities offer life-saving benefits for patients through access to previously undruggable targets. Yet these modalities pose a challenge for the pharmaceutical industry, as side effects are complex, unpredictable, and often uniquely human. With animal studies having limited predictive value due to translatability challenges, the pharmaceutical industry seeks out new approach methodologies. Microphysiological systems (MPS) offer important features that enable complex toxicological processes to be modeled in vitro such as (a) an adjustable complexity of cellular components, including immune components; (b) a modifiable tissue architecture; (c) integration and monitoring of dynamic mechanisms; and (d) a multiorgan connection. Here we review MPS studies in the context of four clinical adverse events triggered by new drug modalities: peripheral neuropathy, thrombocytopenia, immune-mediated hepatotoxicity, and cytokine release syndrome. We conclude that while the use of MPS for testing new drug modality-induced toxicities is still in its infancy, we see strong potential going forward.","PeriodicalId":8057,"journal":{"name":"Annual review of pharmacology and toxicology","volume":" ","pages":""},"PeriodicalIF":11.2,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142124645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

PROTACs as Therapeutic Modalities for Drug Discovery in Castration-Resistant Prostate Cancer. PROTACs 作为阉割耐药前列腺癌药物发现的治疗模式。

IF 11.2 1区医学

Annual review of pharmacology and toxicology Pub Date : 2024-08-08 DOI: 10.1146/annurev-pharmtox-030624-110238

Ling-Yu Wang, Chiu-Lien Hung, Tsan-Chun Wang, Hung-Chih Hsu, Hsing-Jien Kung, Kwang-Huei Lin

{"title":"PROTACs as Therapeutic Modalities for Drug Discovery in Castration-Resistant Prostate Cancer.","authors":"Ling-Yu Wang, Chiu-Lien Hung, Tsan-Chun Wang, Hung-Chih Hsu, Hsing-Jien Kung, Kwang-Huei Lin","doi":"10.1146/annurev-pharmtox-030624-110238","DOIUrl":"https://doi.org/10.1146/annurev-pharmtox-030624-110238","url":null,"abstract":"Castration-resistant prostate cancer (CRPC) presents significant challenges in clinical management due to its resistance to conventional androgen receptor (AR)-targeting therapies. The advent of proteolysis targeting chimeras (PROTACs) has revolutionized cancer therapy by enabling the targeted degradation of key molecular players implicated in CRPC progression. In this review we discuss the developments of PROTACs for CRPC treatment, focusing on AR and other CRPC-associated regulators. We provide an overview of the strategic trends in AR PROTAC development from the aspect of targeting site selection and preclinical antitumor evaluation, as well as updates on AR degraders in clinical applications. Additionally, we briefly address the current status of selective AR degrader development. Furthermore, we review new developments in PROTACs as potential CRPC treatment paradigms, highlighting those targeting chromatin modulators BRD4, EZH2, and SWI/SNF; transcription regulator SMAD3; and kinases CDK9 and PIM1. Given the molecular targets shared between CRPC and neuroendocrine prostate cancer (NEPC), we also discuss the potential of PROTACs in addressing NEPC.","PeriodicalId":8057,"journal":{"name":"Annual review of pharmacology and toxicology","volume":" ","pages":""},"PeriodicalIF":11.2,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141905651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharma[e]cology: How the Gut Microbiome Contributes to Variations in Drug Response. 制药学：肠道微生物组如何导致药物反应的变化。

IF 11.2 1区医学

Annual review of pharmacology and toxicology Pub Date : 2024-08-06 DOI: 10.1146/annurev-pharmtox-022724-100847

Kai R Trepka, Christine A Olson, Vaibhav Upadhyay, Chen Zhang, Peter J Turnbaugh

引用次数: 0